Home › Funds › ORBIMED ADVISORS LLC › CRVS
ORBIMED ADVISORS LLC position in CRVS
CORVUS PHARMACEUTICALS I · Health Care
ORBIMED ADVISORS LLC reported holding 7,165,006 shares of CRVS (CORVUS PHARMACEUTICALS I) in its Q2 2026 13F filing — a position valued at US$107.0M, representing 2.15% of its reported portfolio and ranking #9 among its reported holdings. ORBIMED ADVISORS LLC has disclosed CRVS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's CRVS position evolved
ORBIMED ADVISORS LLC first disclosed a stake in CRVS in Q3 2023 at 6,943,654 shares (US$10.1M). The position peaked in Q2 2026 at 7,165,006 shares, worth US$107.0M. Across 12 filings, ORBIMED ADVISORS LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 7,165,006 shares valued at US$107.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 6.94M | $10.14M | New |
| Q4 2023 | 6.94M | $12.22M | Hold |
| Q1 2024 | 6.94M | $12.36M | Hold |
| Q2 2024 | 6.94M | $12.64M | Hold |
| Q3 2024 | 6.94M | $36.66M | Hold |
| Q4 2024 | 6.94M | $37.15M | Hold |
| Q1 2025 | 6.94M | $22.08M | Hold |
| Q2 2025 | 7.17M | $28.66M | Add |
| Q3 2025 | 7.17M | $52.81M | Hold |
| Q4 2025 | 7.17M | $55.17M | Hold |
| Q1 2026 | 7.17M | $104.82M | Hold |
| Q2 2026 | 7.17M | $107.05M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRVS and 13F data
CRVS (CORVUS PHARMACEUTICALS I) is a Health Care company. 72 other funds we track also report a position in CRVS — the largest reported positions include ADAMS STREET PARTNERS LLC (US$48.9M), Vivo Capital, LLC (US$41.9M), PERCEPTIVE ADVISORS LLC (US$39.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRVS
- ADAMS STREET PARTNERS LLC 3.28M sh · $48.94M · Q2 2026
- Vivo Capital, LLC 2.81M sh · $41.92M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.67M sh · $39.85M · Q2 2026
- Deep Track Capital, LP 2.49M sh · $37.23M · Q2 2026
- BRAIDWELL LP 2.13M sh · $31.77M · Q2 2026
- Foresite Capital Management VI LLC 1.83M sh · $27.36M · Q2 2026
- Boxer Capital Management, LLC 1.10M sh · $16.43M · Q2 2026
- Catalio Capital Management, LP 1.08M sh · $16.15M · Q2 2026
- Eversept Partners, LP 747.99K sh · $11.18M · Q2 2026
- DCF Advisers, LLC 637.50K sh · $9.52M · Q2 2026
- Blue Owl Capital Holdings LP 608.60K sh · $9.09M · Q2 2026
- Nextech Invest Ltd. 450.00K sh · $6.72M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held CRVS?
ORBIMED ADVISORS LLC has disclosed CRVS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ORBIMED ADVISORS LLC's current position in CRVS?
As of Q2 2026, ORBIMED ADVISORS LLC holds 7.17M shares of CRVS (CORVUS PHARMACEUTICALS I), valued at $107.05M, representing 2.15% of its reported portfolio and ranking #9.
Has ORBIMED ADVISORS LLC been buying or selling CRVS?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC held unchanged its position in CRVS. The position peaked in Q2 2026 at 7.17M shares.
Which other funds hold CRVS?
Other major institutional holders of CRVS include ADAMS STREET PARTNERS LLC, Vivo Capital, LLC, PERCEPTIVE ADVISORS LLC, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.